Maralixibat - Mirum Pharmaceuticals
Alternative Names: CAN 108; GC-2127A; LIVMARLI; Lopixibat - Mirum Pharmaceuticals; Lopixibat chloride - Mirum Pharmaceuticals; LUM-001; Maralixibat chloride - Mirum Pharmaceuticals; SD-5613; SHP 625; TAK-625Latest Information Update: 29 Aug 2024
At a glance
- Originator Pfizer
- Developer CANbridge Pharmaceuticals; GC Biopharma; Mirum Pharmaceuticals; Pfizer; Takeda
- Class Amines; Anti-inflammatories; Antihyperlipidaemics; Azabicyclo compounds; Benzothiepins; Dioxoles; Hepatoprotectants; Onium compounds; Small molecules
- Mechanism of Action Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Alagille syndrome; Intrahepatic cholestasis
- Phase II Biliary atresia
- Discontinued Hypercholesterolaemia; Primary biliary cirrhosis; Primary sclerosing cholangitis
Most Recent Events
- 29 Aug 2024 Preregistration for Intrahepatic cholestasis (In adolescents, In children, In the elderly, In infants, In adults) in Japan (PO)
- 14 Aug 2024 Mirum Pharmaceuticals plans a phase III trial for Pruritus (In infants, In Children, In adults, In the elderly) in USA, Brazil, France, Italy, Lebanon, Mexico, Poland, Spain, United Kingdom (PO) (NCT06553768)
- 07 Aug 2024 Mirum Pharmaceuticals plans a phase-III EXPAND trial for Intrahepatic cholestasis in the second half of the 2024 (PO).